Genprex collaborates with Roche Diagnostics to validate TROP2/PTEN biomarkers for NSCLC

Genprex, Inc.

Collaboration with Roche Diagnostics to validate TROP2 and PTEN biomarkers for patient selection in NSCLC clinical trials.
Roche's AI-driven companion diagnostic received FDA Breakthrough Device Designation; Genprex will use same TROP2 antibody.
Validation studies expected to complete by end of 2026, with subsequent integration into NSCLC clinical program.
Preclinical data: high TROP2 H-scores and low PTEN H-scores predicted response; clinical data correlated with longer PFS.
Goal to shorten patient identification and recruitment for NSCLC trials, enabling more personalized treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.